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Abstract
Background: Multinodular goitre (MNG) is a common disorder characterised by an enlargement
of the thyroid, occurring as a compensatory response to hormonogenesis impairment. The
incidence of MNG is dependent on sex (female:male ratio 5:1) and several reports have
documented a genetic basis for the disease. Last year we mapped a MNG locus to chromosome
Xp22 in a region containing the peroxiredoxin IV (Prx-IV) gene. Since Prx-IV is involved in the
removal of H2O2 in thyroid cells, we hypothesize that mutations in Prx-IV gene are involved in
pathogenesis of MNG.
Methods: Four individuals (2 affected, 2 unrelated unaffected) were sequenced using automated
methods. All individuals were originated from the original three-generation Italian family described
in previous studies. A Southern blot analysis using a Prx-IV full-length cDNA as a probe was
performed in order to exclude genomic rearrangements and/or intronic mutations. In addition a
RT-PCR of PRX-IV was performed in order to investigate expression alterations.
Results:  No causative mutations were found. Two adjacent nucleotide substitutions were
detected within introns 1 and 4. These changes were also detected in unaffected individuals,
suggesting that they were innocuous polymorphisms. No gross genomic rearrangements and/or
restriction fragment alterations were observed on Southern analysis. Finally, using RT-PCR from
tissue-specific RNA, no differences of PRX-IV expression-levels were detected between affected
and unaffected samples.
Conclusions: Based on sequence and genomic analysis, Prx-IV is very unlikely to be the MNG2
gene.
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Background
Multinodular goiter (MNG, OMIM *138800) is a com-
mon disorder, arising as a compensatory response to an
impairment of thyroid hormonogenesis. Affected individ-
uals maintain normal hormone levels by an increase in
thyroid activity and mass, so that they are eu-metabolic
but goitrous [1]. Even if MNG incidence is influenced by
iodine intake, family clustering of the disease has been re-
ported in iodo-sufficient areas, suggesting a genetic basis
for the disease [2]. This was confirmed by the identifica-
tion of three dominant MNG loci: MNG1 on chromo-
some 14q [3], MNG2 on chromosome Xp22 [4] and
MNG3 on chromosome 3q26 [5]. The MNG2 locus maps
to a 9.6 cM interval containing the peroxiredoxin-IV (Prx-
IV, formerly known as AOE372) gene. Peroxiredoxins are
a family of highly conserved anti-oxidant enzymes, reduc-
ing hydrogen peroxide and/or organic hydroperoxides
[6]. In thyroid cells, regulation of H2O2 concentration is
critical for the thyroxine synthesis, since hydrogen perox-
ide is needed for the conversion of iodide to organically
bound iodine. Since PRX-I e PRX-II are involved in the re-
moval of H2O2 in thyroid cells, we have hypothesised that
Prx-IV mutations may affect intracellular H2O2 levels and
impair thyroxine hormonogenesis. Therefore, we have
screened Prx-IV as a MNG2 positional candidate.
Methods
Direct sequencing
We have sequenziated four individuals (2 affected, 2 un-
related unaffected) originated from the large family that
allowed the MNG2 locus assignment [4].
Intronic primers pairs amplifying Prx-IV exons were de-
signed (Table 1), based on the genomic structure reported
by Wong et al.[6]. One primers pair amplifying 500 bp of
putative promoter was also selected (Table 1). Intron and
5'UTR sequences were obtained, using the BLAST program
to match Prx-IV mRNA (accession n. XM_041446) against
the "htgs" database of genomic sequences. The most likely
location of the promoter was assessed using the SCAN
SIGNAL software. PCR products were sequenced with the
CEQ™ DTCS Kit (Beckman-Coulter, CA, USA) and run on
a CEQ2000 automated sequencer (Beckman-Coulter, CA,
USA).
Southern blot
5 µg genomic DNA were digested using EcoRI and Hind III.
Digests were electrophoresed on 1.0% agarose gels, and
the DNA was subsequently transferred to Hybond N+ fil-
ter membranes (Amersham), with 10 ×  SSC as transferring
buffer. Probes were labeled, by random priming, with
32P-dCTP. Membranes were hybridized overnight at
65°C. Final washing of the membranes was performed
with 0.1 ×  SSC at 65°C. The results were analyzed with the
STORM Phosphor Imaging System.
FNAB and RT-PCR
Patients were placed in the recumbent position with a pil-
low under their shoulders, such that their neck was hyper-
extended, and the skin cleansed with povidone iodine
(Betadina scrub). The nodules was fixed in position man-
ually, and a 23 gauge needle attacched to a 20 ml dispos-
able syringe inserted perpendicular to the anterior surface
of the neck. Once the needle was in place, costant suction
was applied and maintained while the needle was with-
drawn to the level of the nodules capsule. The content was
then discharged onto glass slides and smears were made.
FNAB samples were then washed twice with 1 ×  PBS and
then processed for RNA extraction. Approximately 1 µg of
RNA was incubated at 42°C for 1 hour with 2.5 µM ran-
dom hexamers (Pharmacia, LKB, Uppsala), 25 U of Rnase
inhibitor (Rnasin, Promega, Madison, WI), 2.5 µl of 10
mM each dNTPs, 4 µl of 5 ×  AMV RT (Promega, Madison,
WI) in a final volume of 20 µl. The cDNA was next ampli-
fied by PCR for PRX-IV gene using primers showed in ta-
Table 1: Forward and reverse PCR primers used for amplification of the coding and promoter regions of PRX-IV
Exon number Exon size (bp) cDNA position Primer sequence PCR size
1 241 1 F taggtgagaaccaggcccgcccagg R gtcgtgcacgcggttgtagctgc 457
2 118 242 F ataatttgtttgatactcctg R ctgccaaagagatctaaaggtagc 307
3 117 360 F gctattcctgaattgtctg R acagtcttttagactactcc 396
4 123 477 F ttgagctaccgtgcctggc R aggtaagcgttctgtttg 281
5 131 608 F gtaaataatcagaaaactttgg R gcatccttttgtgtggatgg 326
6 35 643 Fctcctgacctcgtgatctgc R gctgaaggtaactgaattctg 226
7 48 691 F tttggcatcagtgtctaacgc R tttagtcaaggcatgggc 298
cDNA 13 F caagggacgtgtttctgcgc R cagctggatctgggattatc 815
Promoter region -936 F gctgtctttgaaacaatag R tgtatacattcgtgggatgc 475BMC Medical Genetics 2002, 3 http://www.biomedcentral.com/1471-2350/3/5
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ble 1. As a positive control we coamplified the
constitutively expressed enzyme glyceraldeide 3-phos-
phate dehydrogenase (GAPDH).
The intensity of the amplified fragments was compared by
scanning using a Molecular Dynamics (Sunnyvale, CA)
densitometer (ImageQuant).
Results
We have carried out Prx-IV mutational analysis in the
three-generation Italian pedigree that allowed the MNG2
locus assignment [4]. Prx-IV is a cytoplasmatic thioredox-
in peroxidase that detoxifies hydrogen peroxide in a redox
chain leading to NADPH oxidation [7]. Therefore, Prx-IV
appears an attractive MNG candidate, since thyroxine syn-
thesis requires hydrogen peroxide.
Patient sequencing identified two adjacent substitutions
in intron 1 (IVS1-9G>A and IVS1-10A>T), and one in in-
tron 4 (IVS4+81T>C). All variants were also found in one
unrelated unaffected male, thus ruling out the hypothesis
that any of them might be disease-related. Coding region
analysis failed to detect any additional substitutions and
moreover promoter region analysis didn't detect other
substitutions. Since the affected females carrying both al-
leles at intron 2 variants, the occurrence of a large gene de-
letion can be excluded. In addition, as shown in figure 1,
no gross PRX-IV rearrangements were detected by South-
ern blot analysis.
Expression analysis using amplified PRX-IV cDNA re-
vealed a single PCR product of the expected size. An equal
relative ratio of intensity with a value 0.86 was detected
when this product was compared with GAPDH cDNA
used as a control (Data not shown).
Discussion and Conclusions
Altogether our data indicate that Prx-IV is very unlikely to
be the MNG2 gene.
The MNG2 region does not contain any additional obvi-
ous candidate, but many ESTs map to the critical interval.
Thus, our future research will be devoted to the identifica-
tion and characterization of those MNG2 ESTs that are ex-
pressed in the thyroid.
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